Outcomes of patients with metastatic gastrointestinal stromal tumors (GIST) treated with multi-kinase inhibitors other than imatinib as first-line treatment

Imatinib is the standard first-line therapy in metastatic gastrointestinal stromal tumours (GIST). Investigational multi-kinase inhibitors (MKIs) such as nilotinib, dasatinib or masitinib have been tested as first-line therapies in phase II/III studies. This might theoretically result either in incr...

Full description

Saved in:

Bibliographic Details
Published in:	ESMO open Vol. 5; no. 6; p. e001082
Main Authors:	Boilève, Alice, Dufresne, Armelle, Chamseddine, Ali, Nassif, Elise, Dumont, Sarah, Brahmi, Medhi, Adam, Julien, Rouleau, Etienne, Karanian, Marie, Haddad, Véronique, Faron, Matthieu, Honoré, Charles, Meeus, Pierre, Le Cesne, Axel, Blay, Jean-Yves, Mir, Olivier
Format:	Journal Article
Language:	English
Published:	England Elsevier Ltd 01.01.2020 BMJ Publishing Group Elsevier
Subjects:	Adult Aged Aged, 80 and over clinical trials Female gastrointestinal stromal tumors Gastrointestinal Stromal Tumors - drug therapy Gastrointestinal Stromal Tumors - genetics Humans imatinib Imatinib Mesylate - therapeutic use Male Middle Aged Mutation Neoplasm Recurrence, Local Original Research protein kinase inhibitors Receptor, Platelet-Derived Growth Factor alpha - genetics Retrospective Studies sarcoma Young Adult gastrointestinal stromal tumors imatinib clinical trials sarcoma protein kinase inhibitors
ISSN:	2059-7029, 2059-7029
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!